ACE inhibitors have achieved widespread usage in the treatment of cardiovascular and
renal disease. ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive …

When first introduced in 1981, angiotensin-converting enzyme (ACE) inhibitors were
indicated only for treatment of refractory hypertension. Since then, they have been shown to …

The chemistry, pharmacology, pharmacokinetics, adverse effects, and dosages of the three
currently available angiotensin-converting enzyme (ACE) inhibitors are reviewed. This class …

Most guidelines for the management of patients with cardiovascular disease recommend
angiotensin-converting enzyme (ACE) inhibitors as first-choice therapy, whereas …

Proven cardiovascular benefit from angiotensin-converting enzyme (ACE) inhibition is a
cornerstone of evidence-based medicine. The first study to show dramatic benefits from ACE …

• The most familiar angiotensin-converting enzyme subtype, angiotensin-converting enzyme-
1 (kininase II), cleaves the vasoconstrictor octapeptide angiotensin II from its inactive …

ACE inhibitors are taken by thousands of patients and have been shown to be very safe.
However, all medications have side effects, and there are some for which patients should be …

Introduction of the first angiotensin-converting enzyme (ACE) inhibitor, captopril, in 1981
marked a major advance in the treatment of essential hypertension. This article reviews the …

Recently there has been extensive development of orally active angiotensin converting
enzyme (ACE) inhibitors in addition to those already marketed, for example, captopril …

The pharmacology of angiotensin-converting-enzyme (ACE) inhibitors and their role in the
renin-angiotensin system (RAS) are described, and pharmacokinetic properties and …